NEU
Director Trades
| Date | Director | Value |
|---|---|---|
| J. Basile | $153,159 |
Company News
Neuren Pharmaceuticals to receive significant royalties on back of DAYBUE sales surge
Neuren Pharmaceuticals (ASX: NEU) is expecting to receive increasing royalty payments from its US partner Acadia Pharmaceuticals, with sales of the recently launched DAYBUE treatment continuing to surge. The Australian pharmaceutical company developed a unique Rett syndrome treatment and granted an exclusive worldwide licence to Acadia for the development and commercialisation of its trofinetide breakthrough, […]
Tabcorp and Entain rumoured to bid for PointsBet, FDA approves Neuren’s Rett drug and IPH dives on cyber security breach
Sources close to PointsBet’s (ASX: PBH) Australian arm have revealed potential acquisition bids are in the works from one of the world’s largest betting and gaming groups Entain (LSE: ENT) and another from major Australian wagering group Tabcorp (ASX: TAH). Potential bids from Entain and Tabcorp follow PointsBet’s confirmation in late December it was in […]
Neuren Pharmaceuticals receives FDA approval for world-first drug to treat Rett syndrome
Melbourne-based Neuren Pharmaceuticals (ASX: NEU) has announced its North American partner Acadia Pharmaceuticals (NASDAQ: ACAD) has received US Food and Drug Administration (FDA) approval for Neuren’s lead candidate Daybue (trofinetide) to treat Rett syndrome in adult and paediatric patients. The drug is the world’s first and only approved treatment for Rett syndrome and is expected […]
Neuren Pharma granted orphan drug status for treatment of Phelan-McDermid, Pitt Hopkins and Angelman syndromes
A drug developed by Neuren Pharmaceuticals (ASX: NEU) to treat debilitating childhood neurodevelopmental disorders has been granted orphan drug designation by the US Food and Drug Administration. Drug candidate NNZ-2591 has previously demonstrated positive results in separate mouse models of Phelan-McDermid, Pitt Hopkins and Angelman syndromes. Currently there are no drug therapies approved for these […]
Neuren’s NNZ-2591 drug candidate alleviates Pitt Hopkins and Angelman syndrome symptoms
Neuren Pharmaceuticals (ASX: NEU) has revealed positive pre-clinical results for its NNZ-2591 drug candidate in treating Pitt Hopkins and Angelman syndromes. According to Neuren, its NNZ-2591 drug is a synthetic analogue of the neurotrophic peptide cyclic glycine proline, which occurs naturally in the brain. In addition to having a positive effect on Pitt Hopkins and […]
Neuren Pharmaceuticals receives first payment in Rett drug licence deal
Neuren Pharmaceuticals (ASX: NEU) has received the first US$10 million payment under a recently announced licence deal with US-based ACADIA Pharmaceuticals to develop its drug trofinetide to treat patients with Rett syndrome. The Melbourne-based biopharmaceutical company announced its agreement with ACADIA earlier this month, granting the latter the exclusive rights to develop and commercialise the […]
FDA greenlights Neuren Pharmaceuticals to kick-off next trial for Rett drug
Melbourne-based Neuren Pharmaceuticals (ASX: NEU) reported the US Food and Drug Administration has given the greenlight for the company to start phase three trials for its drug trofinetide, which is used to treat people with Rett syndrome. Neuren Pharmaceuticals executive chairman Richard Treagus said the FDA meeting provided necessary confirmation on key issues relating to […]
Company Videos
No videos found.